303 related articles for article (PubMed ID: 35963564)
1. Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer.
Yin X; Liao H; Yun H; Lin N; Li S; Xiang Y; Ma X
Semin Cancer Biol; 2022 Nov; 86(Pt 2):146-159. PubMed ID: 35963564
[TBL] [Abstract][Full Text] [Related]
2. Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives.
Yang Y; Liu H; Chen Y; Xiao N; Zheng Z; Liu H; Wan J
Cell Death Dis; 2023 Mar; 14(3):230. PubMed ID: 37002211
[TBL] [Abstract][Full Text] [Related]
3. Multi-omics and artificial intelligence predict clinical outcomes of immunotherapy in non-small cell lung cancer patients.
Mei T; Wang T; Zhou Q
Clin Exp Med; 2024 Mar; 24(1):60. PubMed ID: 38554212
[TBL] [Abstract][Full Text] [Related]
4. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
5. The artificial intelligence and machine learning in lung cancer immunotherapy.
Gao Q; Yang L; Lu M; Jin R; Ye H; Ma T
J Hematol Oncol; 2023 May; 16(1):55. PubMed ID: 37226190
[TBL] [Abstract][Full Text] [Related]
6. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
[TBL] [Abstract][Full Text] [Related]
7. Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.
Wiesweg M; Mairinger F; Reis H; Goetz M; Kollmeier J; Misch D; Stephan-Falkenau S; Mairinger T; Walter RFH; Hager T; Metzenmacher M; Eberhardt WEE; Zaun G; Köster J; Stuschke M; Aigner C; Darwiche K; Schmid KW; Rahmann S; Schuler M
Eur J Cancer; 2020 Nov; 140():76-85. PubMed ID: 33059196
[TBL] [Abstract][Full Text] [Related]
8. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
9. Artificial intelligence-powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non-small cell lung cancer with better prediction of immunotherapy response.
Choi S; Cho SI; Ma M; Park S; Pereira S; Aum BJ; Shin S; Paeng K; Yoo D; Jung W; Ock CY; Lee SH; Choi YL; Chung JH; Mok TS; Kim H; Kim S
Eur J Cancer; 2022 Jul; 170():17-26. PubMed ID: 35576849
[TBL] [Abstract][Full Text] [Related]
10. A Review of Artificial Intelligence in Precise Assessment of Programmed Cell Death-ligand 1 and Tumor-infiltrating Lymphocytes in Non-Small Cell Lung Cancer.
Wu J; Lin D
Adv Anat Pathol; 2021 Nov; 28(6):439-445. PubMed ID: 34623343
[TBL] [Abstract][Full Text] [Related]
11. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
Front Immunol; 2021; 12():646874. PubMed ID: 33927719
[TBL] [Abstract][Full Text] [Related]
12. Artificial Intelligence-Assisted Score Analysis for Predicting the Expression of the Immunotherapy Biomarker PD-L1 in Lung Cancer.
Cheng G; Zhang F; Xing Y; Hu X; Zhang H; Chen S; Li M; Peng C; Ding G; Zhang D; Chen P; Xia Q; Wu M
Front Immunol; 2022; 13():893198. PubMed ID: 35844508
[TBL] [Abstract][Full Text] [Related]
13. Predicting EGFR and PD-L1 Status in NSCLC Patients Using Multitask AI System Based on CT Images.
Wang C; Ma J; Shao J; Zhang S; Liu Z; Yu Y; Li W
Front Immunol; 2022; 13():813072. PubMed ID: 35250988
[TBL] [Abstract][Full Text] [Related]
14. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
15. [Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer].
Huang C; Yang X
Zhongguo Fei Ai Za Zhi; 2021 Nov; 24(11):777-783. PubMed ID: 34802209
[TBL] [Abstract][Full Text] [Related]
16. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
Krieger T; Pearson I; Bell J; Doherty J; Robbins P
Diagn Pathol; 2020 Jan; 15(1):6. PubMed ID: 32000815
[TBL] [Abstract][Full Text] [Related]
17. What does radiomics do in PD-L1 blockade therapy of NSCLC patients?
Cui R; Yang Z; Liu L
Thorac Cancer; 2022 Oct; 13(19):2669-2680. PubMed ID: 36039482
[TBL] [Abstract][Full Text] [Related]
18. [Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer].
Lupo A; Alifano M; Wislez M; Boulle G; Velut Y; Biton J; Cremer I; Goldwasser F; Leroy K; Damotte D
Rev Pneumol Clin; 2018 Oct; 74(5):339-350. PubMed ID: 30337201
[TBL] [Abstract][Full Text] [Related]
19. When artificial intelligence meets PD-1/PD-L1 inhibitors: Population screening, response prediction and efficacy evaluation.
Jin W; Luo Q
Comput Biol Med; 2022 Jun; 145():105499. PubMed ID: 35439641
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
